These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33323781)

  • 1. Polymorphism in the MAGI2 Gene Modifies the Effect of Amyloid β on Neurodegeneration.
    Kim HR; Lee T; Choi JK; Jeong Y;
    Alzheimer Dis Assoc Disord; 2021 Apr-Jun 01; 35(2):114-120. PubMed ID: 33323781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.
    Franzmeier N; Ossenkoppele R; Brendel M; Rubinski A; Smith R; Kumar A; Mattsson-Carlgren N; Strandberg O; Duering M; Buerger K; Dichgans M; Hansson O; Ewers M;
    Alzheimers Dement; 2022 Jan; 18(1):103-115. PubMed ID: 34060233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.
    Nho K; Nudelman K; Allen M; Hodges A; Kim S; Risacher SL; Apostolova LG; Lin K; Lunnon K; Wang X; Burgess JD; Ertekin-Taner N; Petersen RC; Wang L; Qi Z; He A; Neuhaus I; Patel V; Foroud T; Faber KM; Lovestone S; Simmons A; Weiner MW; Saykin AJ;
    Alzheimers Dement; 2020 Sep; 16(9):1213-1223. PubMed ID: 32755048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.
    Darst BF; Koscik RL; Racine AM; Oh JM; Krause RA; Carlsson CM; Zetterberg H; Blennow K; Christian BT; Bendlin BB; Okonkwo OC; Hogan KJ; Hermann BP; Sager MA; Asthana S; Johnson SC; Engelman CD
    J Alzheimers Dis; 2017; 55(2):473-484. PubMed ID: 27662287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease.
    Roostaei T; Nazeri A; Felsky D; De Jager PL; Schneider JA; Pollock BG; Bennett DA; Voineskos AN;
    Mol Psychiatry; 2017 Feb; 22(2):287-295. PubMed ID: 27021820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic epistasis regulates amyloid deposition in resilient aging.
    Felsky D; Xu J; Chibnik LB; Schneider JA; Knight J; Kennedy JL; ; Bennett DA; De Jager PL; Voineskos AN
    Alzheimers Dement; 2017 Oct; 13(10):1107-1116. PubMed ID: 28322202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
    Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM
    Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study.
    Ramanan VK; Risacher SL; Nho K; Kim S; Swaminathan S; Shen L; Foroud TM; Hakonarson H; Huentelman MJ; Aisen PS; Petersen RC; Green RC; Jack CR; Koeppe RA; Jagust WJ; Weiner MW; Saykin AJ;
    Mol Psychiatry; 2014 Mar; 19(3):351-7. PubMed ID: 23419831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity.
    Avants BB; Hutchison RM; Mikulskis A; Salinas-Valenzuela C; Hargreaves R; Beaver J; Chiao P;
    Neurobiol Aging; 2019 Feb; 74():191-201. PubMed ID: 30471630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polygenic risk of Alzheimer disease is associated with early- and late-life processes.
    Mormino EC; Sperling RA; Holmes AJ; Buckner RL; De Jager PL; Smoller JW; Sabuncu MR;
    Neurology; 2016 Aug; 87(5):481-8. PubMed ID: 27385740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
    Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.